-
LEMBAZ™ (adrabetadex) is the first medicine to address the underlying cholesterol trafficking defect that causes Niemann-Pick disease, type C
-
LEMBAZ reduced risk of death by 55% compared to matched external controls
-
Beren launches Caregiver Ambassador Program & LEMBAZ Family Support to help families find a treatment site, navigate insurance and logistics, provide financial assistance
-
Beren received a Priority Review Voucher upon approval
THOUSAND OAKS, Calif., November 17, 2026 – Beren Therapeutics P.B.C., a leader in cholesterol-trafficking biology and novel cyclodextrin-based therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has approved LEMBAZTM (adrabetadex), the first medicine to address the underlying cholesterol trafficking defect that causes Niemann-Pick disease, type C (NPC) and the first medicine to improve survival in infantile-onset NPC (I-NPC). LEMBAZ is approved for adults and children with NPC who had neurological manifestations that started before the age of 6. The company received a Priority Review Voucher upon this approval.
“For children and families with infantile-onset NPC, this long-awaited approval brings a new kind of hope for the future,” said Heather Moran-Teal, Executive Director of National Niemann Pick Disease Foundation. “LEMBAZ represents an important step forward in the treatment of this devastating disease. For families who know how precious time can be, these encouraging survival findings carry profound meaning and hope for more time together.”
NPC is a rare, devastating neurodegenerative disorder marked by progressive neurological decline and premature death. It is caused by defective proteins that are unable to transport intracellular cholesterol. As a result, cholesterol becomes trapped in parts of the cell and is not properly distributed to where it is needed for normal cell function, with the most severe and debilitating effects occurring in the brain and nervous system. By re-establishing intracellular cholesterol trafficking, LEMBAZ addresses the underlying cause of NPC.
“Niemann-Pick disease, type C is incredibly devastating, gradually robbing those who have the condition of all of their abilities, leaving them debilitated and cutting short their lives far too soon. Because neurological function that is lost cannot be regained, early diagnosis and prompt treatment are critical,” said Elizabeth M. Berry-Kravis, M.D., Ph.D., Professor of Pediatrics and Neurological Sciences at Rush University Medical Center and lead investigator for the Expanded Access Program. “For the first time, LEMBAZ gives clinicians a way to address the underlying cholesterol trafficking defect that causes infantile-onset NPC, where early intervention can make the greatest difference. As the only NPC medicine to improve survival, LEMBAZ gives children more time to be children, more time with their families, more time to live life.”
The efficacy of LEMBAZ was based on an overall survival analysis in people with I-NPC treated with LEMBAZ across three clinical studies and an Expanded Access Program, compared with matched external controls. The FDA determined that this comparison served as the adequate and well-controlled study supporting approval. The analysis showed a 55 percent reduction in the risk of mortality.
“We are delighted to celebrate this moment with the NPC community. This approval reflects nearly two decades of extraordinary determination by the global NPC community, alongside the contributions of patients, families, physicians, researchers and organizations who helped advance this medicine. We appreciate the close collaboration with the FDA over the last 5 years to develop a rigorous approach to evaluating more than a decade of clinical evidence. That scientific work was fundamental to reaching this milestone,” said Jason Camm, Chief Executive Officer of Beren Therapeutics P.B.C. “At Beren, we have always understood that developing a medicine is only one part of treating a disease. That’s why we’ve been building the system around it, helping families reach a diagnosis sooner, access treatment faster, and receive the care and support they need.”
About LEMBAZTM (adrabetadex)
LEMBAZ™ (adrabetadex) is the first FDA approved medicine to address the underlying cholesterol trafficking defect that causes Niemann-Pick disease, type C (NPC). LEMBAZ targets the cholesterol that builds up inside brain cells, which drives the neurological damage in NPC, by replacing the function of the NPC protein that is not working properly and helps move cholesterol to where the cell can use it.
About Niemann-Pick Disease, Type C
Niemann-Pick disease, type C (NPC) is a rare, devastating neurodegenerative disorder marked by progressive neurological decline and premature death. It is caused by defective proteins that are unable to sufficiently transport intracellular cholesterol. As a result, cholesterol becomes trapped in parts of the cell and is not properly distributed to where it is needed for normal cell function, with the most severe and debilitating effects occurring in the brain and nervous system. In the U.S., approximately half of those living with NPC – 475 children – have infantile-onset NPC (I‑NPC), which is when the neurological signs appear before a child’s sixth birthday and is the most severe and rapidly progressive form of the disease. Earlier neurological onset is associated with more rapid disease progression and earlier mortality with mean ages of death of ~5.6 years for early infantile-onset (age of neurological onset <2 years) and ~13.4 years for late-infantile onset (2 to <6 years). Because diagnosis is often delayed, earlier recognition and prompt initiation of treatment are critical priorities.
About Beren Therapeutics P.B.C.
Beren Therapeutics P.B.C. is a founder-led biotechnology company pioneering the discovery, development and commercialization of cyclodextrin-based medicines for diseases driven by defective cholesterol trafficking. As a fully integrated organization, Beren is committed to translating insights from the patient community and the laboratory into the development and delivery of transformative medicines. Beren and its subsidiary Mandos LLC® have supported the NPC community by providing access to adrabetadex through an Expanded Access Program (EAP).
Beren is a Public Benefit Corporation purpose-built to bring life-changing medicines to patients as quickly and responsibly as possible. Its P.B.C. structure is intended to align governance with long-term patient impact, empowering its leadership team and Board to balance the interests of patients, caregivers, clinicians and health systems alongside long-term shareholder value.
Beren is headquartered in Thousand Oaks, Calif.